 | | Key Catalysts Are Ready To Send ADVENTRX Shares Higher
|
| | ADVENTRX Pharmaceuticals (AMEX:ANX) is a company that is rarely mentioned among the bigger players, though this may soon change as it gains attention leading into its 2011 product pipeline catalysts. Leading into the new year, the stock seemed poised to make new 52-week highs as it announced the much anticipated positive 12-month results for ANX-530, was awarded a $500,000 grant, and marketed itself at numerous healthcare & pharma conferences. These events quickly took the share price from $2 to $3 in a matter of weeks, leaving potential investors hungry for the new year. Currently sitting at a market cap of only $32.5M, the potential to grow exponentially is beginning to make waves among expert biotech investors. The flagship product, ANX-530 or Exelbine, for the treatment of non-small cell lung cancer, is a novel emulsion formulation of the already approved drug vinorelbine. Sales of non-small-cell lung cancer (NSCLC) drugs will increase from around $4 billion in 2009 to more than $6.5 billion in 2019 in the leading markets of the USA, France, Germany, Italy, Spain, UK and Japan, according to health care advisory firm Decision Resources. This represents a significant upside potential in the company’s market cap, and more importantly, the fact that it uses a currently approved formulation drug leaves it highly likely that the FDA will approve it for commercialization. As far as its financial standing goes, the company enjoys a sound balance sheet, with $30M cash on hand, a low burn rate of roughly $5M per year, and little to no debt at $1.7M, it seemed that the possibility of raising capital was nearly extinct. With key FDA catalysts expected on 9/1/11 for PDUFA of Exelbine (ANX-530, non-small cell lung cancer), and 1st quarter FDA meeting for ANX-514 (decrease chemo side-effects drug, a $2 billion dollar market), the stock seemed poised to enjoy a nice run up in price in anticipation of positive news. Then, just as soon as the stock hit a high of $3.40, on 1/7/11, retail investors cringed as ADVENTRX announced a capital raise of $22.5M from RA Capital Management, healthcare-focused specialists at a per unit purchase of $2.75. | |
| | |  | | | Latest Updates
| | - $ANX nears major upcoming FDA catalysts
- $APRI and $SPPI also placed on high breakout alerts
|  |
| |
|  |
| |
No comments:
Post a Comment